View More Recent Stories
-
Amylyx Pharmaceuticals (AMLX) Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
-
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q2 EPS by 34c
-
H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
-
Amylyx Pharmaceuticals (AMLX) Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
-
H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
